Olema Pharmaceuticals, Inc. (OLMA) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
2.75
↑+42% vs avg
5yr avg: 1.94
30Y Low0.5·High5.6
ROE
↓
-36.6%
↓+1% vs avg
5yr avg: -37.0%
30Y Low-43%·High-14%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
OLMA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Olema Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.2B | $2.2B | $342M | $635M | $98M | $370M | $1.9B | — | — |
| Enterprise Value | $1.2B | $2.1B | $204M | $569M | $77M | $359M | $1.6B | — | — |
| P/E Ratio → | -8.09 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 2.75 | 4.55 | 0.84 | 2.50 | 0.50 | 1.30 | 5.59 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
OLMA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
OLMA Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -36.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -36.6% | -36.6% | -39.1% | -42.8% | -43.5% | -22.8% | -13.5% | — | — |
| ROA | -33.0% | -33.0% | -35.6% | -39.2% | -41.0% | -22.3% | -12.9% | -253.7% | -67.2% |
| ROIC | -38.2% | -38.2% | -46.5% | -43.2% | -35.6% | -39.2% | — | — | — |
| ROCE | -40.1% | -40.1% | -42.8% | -46.2% | -44.0% | -22.9% | -12.8% | -474.0% | -67.7% |
OLMA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $48M exceeds total debt of $1M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.10 | -0.34 | -0.26 | -0.11 | -0.04 | -1.00 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -32.97 | — | -74.25 |
Net cash position: cash ($48M) exceeds total debt ($1M)
OLMA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Olema Pharmaceuticals, Inc.'s current ratio of 9.95x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 12.33x to 9.95x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.95 | 9.95 | 10.50 | 12.33 | 12.62 | 32.23 | 74.62 | 0.07 | 16.13 |
| Quick Ratio | 9.95 | 9.95 | 10.50 | 12.33 | 12.62 | 32.23 | 74.62 | 0.07 | 16.13 |
| Cash Ratio | 9.76 | 9.76 | 10.40 | 12.11 | 12.35 | 31.85 | 73.84 | 0.05 | 15.67 |
| Asset Turnover | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
OLMA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Olema Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | — | — |
| Shares Outstanding | — | $87M | $59M | $45M | $40M | $40M | $39M | $40M | $14M |
Peer Comparison
Compare OLMA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 OLMAYou | $1B | -8.1 | — | — | — | — | -36.6% | -38.2% | — |
 SRRK | $5B | -14.1 | — | — | — | — | -123.1% | -201.2% | — |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 RVMD | $30B | -24.0 | — | — | — | — | -58.1% | -54.3% | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 NUVL | $8B | -17.5 | — | — | — | — | -36.7% | -32.5% | — |
 TNGX | $3B | -27.0 | — | — | 96.3% | -178.4% | -37.2% | -38.5% | — |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 ARVN | $652M | -8.0 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 ORIC | $912M | -6.0 | — | — | — | — | -41.3% | -39.9% | — |
 PTGX | $6B | -48.2 | — | 113.4 | 97.3% | -343.6% | -20.2% | -21.8% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See OLMA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs OLMA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare OLMA vs SRRK
Side-by-side business, growth, and profitability comparison vs Scholar Rock Holding Corporation.
Start ComparisonOLMA — Frequently Asked Questions
Quick answers to the most common questions about buying OLMA stock.
What is Olema Pharmaceuticals, Inc.'s P/E ratio?
Olema Pharmaceuticals, Inc.'s current P/E ratio is -8.1x. This places it at the 50th percentile of its historical range.
What is Olema Pharmaceuticals, Inc.'s ROE?
Olema Pharmaceuticals, Inc.'s return on equity (ROE) is -36.6%. The historical average is -33.1%.
Is OLMA stock overvalued?
Based on historical data, Olema Pharmaceuticals, Inc. is trading at a P/E of -8.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.